Teva CEO: We are in talks to co-produce the Covid-19 vaccine

The CEO of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) told Reuters that the Israeli pharmaceutical company is in talks with manufacturers of Covid-19 vaccine to participate in the production of their vaccine. He said, “We have some discussions with the originators of the original vaccines. We haven’t reached any conclusion.” Related materials Teva is preparing to distribute the Covid-19 vaccine in Israel, as Teva beat expectations with strong fourth-quarter results. He added, “In principle, we are positive about contributing by manufacturing some of these vaccines that have either been approved or are about to be approved.” Schultz told Reuters that Teva contacted and contacted vaccine manufacturers, but he refused. About naming the companies that negotiate with them. He also talked about the matter to “Bloomberg”, telling them that Teva had offered to dedicate its manufacturing capacity in the United States, Europe and elsewhere to assist in mass immunization efforts directed at fighting the epidemic. “We have a wide global network of manufacturing capabilities, from creating the base drug to putting the solution in sterile vials, known as the final filling process. Manufacturing, and building it takes time,” he said. Teva is already considered an integral part of the Israeli launch of the Covid-19 vaccination, which has seen 3.61 million people vaccinated, including 2.22 million people who have already received a second dose. The SLE unit at Teva is responsible for the logistics and distribution of the Pfizer vaccine in Israel, which must be kept at -70 ° C before use. Posted by Globes, Israel business news – en.globes.co.il – February 10, 2021 © Copyright Globes Publisher Itonut (1983) Ltd. 2021